{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:30:56Z","timestamp":1772155856647,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>There are no established guidelines for evaluating and treating hypogammaglobulinemia in patients with rheumatic disease who receive B-cell depleting agents. The purpose of this article is to review findings in the work-up and treatment of common variable immunodeficiency (CVID) that can guide our evaluation of patients with autoimmune disease who develop hypogammaglobulinemia after rituximab\/B-cell depleting therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Infection rates are higher in rheumatic disease patients who develop hypogammaglobulinemia than those who do not. However, not all patients who develop hypogammaglobulinemia are at increased risk of developing infection after B-cell depleting therapy. Recent consensus statements have helped refine the diagnosis of impaired immune responses in patients with CVID, and can provide guidance for the diagnostic work-up and therapeutic decision making for patients with secondary drug induced hypogammaglobulinemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Based on findings in studies of CVID, assessment of vaccine response in patients with hypogammglogulinemia after rituximab therapy in the setting of recurrent infections can help predict propensity for infection and thus guide decision making with regards to intravenous immunoglobulin supplementation and retreatment with rituximab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000377","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T11:44:19Z","timestamp":1487936659000},"page":"228-233","source":"Crossref","is-referenced-by-count":38,"title":["Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy"],"prefix":"10.1097","volume":"29","author":[{"given":"Ruba","family":"Kado","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgiana","family":"Sanders","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Departments of Internal Medicine and Pediatrics and Communicable Diseases, University of Michigan, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Joseph","family":"McCune","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","article-title":"Suppression of normal immune responses after treatment with rituximab","volume":"28","author":"Kado","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoS One"},{"key":"R3-20230828","first-page":"1","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","author":"Jolles","year":"2016","journal-title":"Clinical Experimental Immunoloy"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency \u2013 causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International Consensus Document (ICON): common variable immunodeficiency disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/cei.12178","article-title":"New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin","volume":"174","author":"Ameratunga R1","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"1186.e1\u201378","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/00313020801911470","article-title":"B-cell maturation defects in common variable immunodeficiency and association with clinical features","volume":"40","author":"Berglund","year":"2008","journal-title":"Pathology"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaci.2004.10.048","article-title":"The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency","volume":"115","author":"Carsetti","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.clim.2007.04.011","article-title":"Active vaccination in patients with common variable immunodeficiency (CVID)","volume":"124","author":"Goldacker","year":"2007","journal-title":"Clin Immunol"},{"key":"R13-20230828","first-page":"1017","article-title":"Diagnostic criteria for common variable immunodeficiency disorders","volume":"4","author":"Ameratunga","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2009.07669.x","article-title":"Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions","volume":"145","author":"Chapel","year":"2009","journal-title":"Br J Haematol"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S1081-1206(10)60572-8","article-title":"Assessment and clinical interpretation of polysaccharide antibody responses","volume":"99","author":"Paris","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12098-016-2038-x","article-title":"Common variable immunodeficiency","volume":"83","author":"Saikia","year":"2016","journal-title":"Indian J Pediatr"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, antitumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.berh.2015.05.009","article-title":"Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis","volume":"29","author":"Lahiri","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allery Clin Immunol Pract"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar3047","article-title":"Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment","volume":"12","author":"Rehnberg","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fimmu.2015.00032","article-title":"Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients","volume":"6","author":"Wolf","year":"2015","journal-title":"Front Immunol"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2010-01-254417","article-title":"How I treat common variable immune deficiency","volume":"116","author":"Cunningham-rundles","year":"2010","journal-title":"Blood"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jbspin.2015.05.012","article-title":"Low pretreatment B-cell counts are not a risk factor of infection in patient treated with rituximab for autoimmune diseases: an observational study","volume":"83","author":"Lazarou","year":"2016","journal-title":"Joint Bone Spine"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201705000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T01:03:38Z","timestamp":1693184618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201705000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000377","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727381737.793547374","asserted-by":"object"}]},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}